J&J Immunology President On Remicade, Inflectra And The Art Of Contract Negotiations
Janssen Biotech's Immunology President Scott White defended the company's Remicade contracting strategy in an interview and outlined why J&J believes it has been unfairly targeted in an anti-competitive lawsuit filed by rival Pfizer.
You may also be interested in...
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.
The company will present detailed data in the future, but top-line results show statistically significant improvement over placebo at 12 weeks in ulcerative colitis, an increasingly competitive market.
Market Snapshot: Despite the availability of anti-TNF biosimilars, the global market for drugs for psoriatic arthritis will grow to $4.1bn in 2025 due to the entry of new branded drugs at high prices in the US, according to a new Datamonitor Healthcare forecast report.